Verticals / Pharma, medtech & health distribution / Regeneron Pharmaceuticals, Inc.
RP
Regeneron Pharmaceuticals, Inc.
regeneron.com ↗—
Latest disclosed NPS
no score published
0
NPS entries
0 with a number
90%
Retention
8 Feb 2018
2018
Years covered
1 entries in all
In their words
“The first renewal rate remains high at above 90%.”
NPS disclosures (0)
No NPS disclosures yet.
Retention disclosures (1)
8 Feb 2018
Retention90%
Retention rate: 90% (FY2017) — “the first renewal rate remains high at above 90%.”
— Leonard S. Schleifer - Regeneron Pharmaceuticals, Inc., Founder, President and CEO, Regeneron Pharmaceuticals, Inc. · Earnings call, Q4 2017 · 8 Feb 2018 · NI-132AD0D
Earnings call, Q4 2017 ↗Lighthouse companies in Pharma, medtech & health distribution
About these figures
Every figure here was publicly disclosed by the named company: press releases, annual reports, SEC filings, earnings calls and news coverage. Companies tend to publish their NPS when it is good, so these numbers run higher than a true industry average: read them as what leading companies in this vertical say publicly, not as an industry benchmark.
NPS runs from −100 to +100. Retention figures are reported as the company defines them (net revenue retention, gross revenue retention, customer retention rate, churn). Every entry links to its source in the full database.